Dyne Therapeutics Reports Financial Results

By Tamara Parker • Thursday, February 27 10:10 • Permanent Link

Dyne Therapeutics, Inc. has reported its financial results for the fourth quarter and full year of 2024, showcasing significant developments and achievements. The company's cash, cash equivalents, and marketable securities as of December 31, 2024, stood at $642.3 million. Moreover, during the first quarter of 2025, Dyne received net proceeds of approximately $140.6 million from the sale of stock through its at-the-market offering program, ensuring the company's financial stability.

In terms of research and development (R&D) expenses, Dyne reported R&D expenses of $81.8 million for the fourth quarter of 2024, compared to $58.8 million for the same period in 2023. For the full year of 2024, R&D expenses amounted to $281.4 million, as opposed to $210.8 million in 2023.

The general and administrative (G&A) expenses also saw an increase, with G&A expenses amounting to $15.3 million for the fourth quarter of 2024, compared to $8.8 million for the same period in 2023. For the full year of 2024, G&A expenses totaled $62.5 million, up from $31.4 million in 2023.

The net loss for the quarter ended December 31, 2024, was $89.5 million, or $0.88 per basic and diluted share, representing an increase from the net loss of $66.6 million, or $1.09 per basic and diluted share, for the same period in 2023. Similarly, the net loss for the year ended December 31, 2024, amounted to $317.4 million, or $3.37 per basic and diluted share, compared to a net loss of $235.9 million, or $3.95 per basic and diluted share, for the year ended December 31, 2023.

Dyne Therapeutics also highlighted significant progress in its clinical programs, with the achievement of full enrollment of the registrational expansion cohort of the achieve trial of Dyne-101 in DM1 planned for mid-2025. The company is also on track with the enrollment of the registrational expansion cohort of the deliver trial of Dyne-251 in DMD, with completion expected in the first quarter of 2025.

These developments underscore Dyne's commitment to advancing life-transforming therapeutics for individuals affected by genetically driven neuromuscular diseases. Today the company's shares have moved -1.6% to a price of $13.57. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.